Automatic synthesis of 18F-AlF-NOTA-octreotide and PET/CT imaging in neuroendocrine tumor
10.3760/cma.j.cn321828-20201231-00466
- VernacularTitle:18F－AlF－NOTA－奥曲肽自动化合成及神经内分泌肿瘤PET/CT显像
- Author:
Xiaoyan GONG
1
;
Fangfang SUN
;
Fei YU
;
Bo CHEN
;
Hongbo FENG
;
Xuemei DU
Author Information
1. 大连医科大学附属第一医院核医学科 116021
- Keywords:
Neuroendocrine tumors;
Octreotide;
Isotope labeling;
Fluorine radioisotopes;
Positron-emission tomography;
Tomography, X-ray computed
- From:
Chinese Journal of Nuclear Medicine and Molecular Imaging
2022;42(8):478-481
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the automatic synthesis method of 18F-AlF-1, 4, 7-triazacyclononane-1, 4, 7-triacetic acid (NOTA)-octreotide and the imaging in neuroendocrine tumor (NET). Methods:Using the Trasis AllinOne synthesis module, 18F-AlF-NOTA-octreotide was automatically synthesized by chelating 18F-AlF and NOTA-octreotide at 100 ℃, and the quality of the product was analyzed. 18F-AlF-NOTA-octreotide and 18F-FDG PET/CT imaging were performed and compared in one patient with NET (male, 35 years old). Results:The total synthesis time of 18F-AlF-NOTA-octreotide was 35 min with a radiochemical yield of (55.8±1.8%)% (non-decay corrected, n=6), radiochemical purity more than 95% and good stability. The sterility and pyrogen-free of the product met the requirements. Compared with 18F-FDG (the lesion SUV max=3.8, target-to-background (T/B) ratio=1.03), 18F-AlF-NOTA-octreotide could be clearly imaged in the patient with NET with SUV max of 21.7 and T/B ratio of 4.09. Conclusions:The preparation of 18F-AlF-NOTA-octreotide with Trasis Allinone synthesis module is simple, rapid and stable. The product has high radiochemical purity and can meet the needs of clinical application. In vivo18F-ALF-NOTA-octreotide PET/CT imaging in the patient with NET shows higher T/B ratio, which has obvious advantages compared with 18F-FDG.
